Global Accelerator for Paediatric Formulations Network (GAP-f)

Global Accelerator for Paediatric Formulations Network (GAP-f)

GettyImages
© Credits

About us

GAP-f is a WHO Network hosted within the Research for Health Department in the Science Division and was created to respond to the paediatric treatment gap.

Following the resolution at the 69th World Health Assembly on promoting innovation and access to quality, safe, efficacious and affordable medicines for children, GAP-f was conceived to build on and formalize the model developed within the HIV community to provide a sustainable mechanism that ensures that safer, more effective, and more durable paediatric formulations are developed and made available to children against an accelerated timeline.

At GAP-f, Children are at the top of our agenda. While there have been significant achievements in child health with six million fewer children under the age of five years dying in 2016 than in 1990, urgent action is needed to achieve the UN Sustainable Development Goals (SDG), particularly SDG 3, which aims to ensure healthy lives and promote wellbeing for all people at all ages and the related target to achieve Universal Health Coverage by 2030.

 

 

News

 

Publications

All →
Paediatric drug optimization for neglected tropical diseases: meeting report, September 2023

Paediatric drug optimization (PADO) exercises aim to identify key priority products and their preferred product characteristics for research and development....

Towards investigation, development and introduction of cefiderocol in children: product brief

Cefiderocol was included in WHO’s PADO priority list because of its efficacy against multiple pathogens in the WHO bacterial priority pathogens list,...

Research and development landscape for childhood cancer: a 2023 perspective

This report provides an overview of the funding and R&D landscape in childhood cancer. The report, based on data from the WHO Global Observatory on...

Paediatric DTG implementation considerations for national programmes

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 mg scored, dispersible tablets,...

GAP-f Secretariat

Contact

For more information email: gap-f@who.int